Poor
Mostly Misaligned
Patient Risk:
Moderate
Summary
Several Vascepa claims partially match label (indication elements, fish-derived EPA and bleeding/monitoring), but multiple statements are unsupported or incorrect relative to the provided prescribing information, especially regarding probiotic interactions and specific interaction claims.
Category Scores
Accurate Statements
Vascepa is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia.
Label 1: “as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.”
Vascepa is associated with an increased risk of bleeding.
Label 5.3: “VASCEPA is associated with an increased risk of bleeding.”
Vascepa contains ethyl esters of omega-3 fatty acid eicosapentaenoic acid (EPA) obtained from fish oil.
Label 5.2: “VASCEPA contains ethyl esters of the omega-3 fatty acid, eicosapentaenoic acid (EPA), obtained from the oil of fish.”
Concomitant antithrombotic medications (e.g., aspirin/clopidogrel/warfarin) are associated with greater bleeding incidence with Vascepa.
Label 5.3: “incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.”
Patients receiving Vascepa and concomitant anticoagulants and/or antiplatelet agents should be monitored for bleeding.
Label 7.1: “Monitor patients receiving VASCEPA and concomitant anticoagulants and/or antiplatelet agents for bleeding.”
Unsupported Statements
Vascepa is a highly purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA).
Provided label excerpt describes ethyl esters of EPA obtained from fish oil but does not state “highly purified form.”
Vascepa works by inhibiting the production of triglycerides in the liver.
Provided label mechanistic language states EPA reduces hepatic VLDL-TG synthesis and/or secretion and enhances TG clearance; it does not specifically claim “inhibiting the production of triglycerides in the liver.”
Vascepa reduces the risk of pancreatitis and other cardiovascular complications.
Label 1 limitation: “effect of VASCEPA on the risk for pancreatitis… has not been determined.” Provided excerpts do not support “reduces the risk of pancreatitis.” Cardiovascular risk reduction is mentioned generally, but the claim as written includes pancreatitis.
Vascepa can thin the blood, increasing the risk of bleeding.
Label 5.3 supports increased bleeding risk; the specific phrasing “thin the blood” is not used/supported in the provided excerpts.
Vascepa can interact with anticoagulants, antiplatelet agents, and NSAIDs.
Provided label 7.1 addresses monitoring with concomitant anticoagulants and/or antiplatelet agents; the provided excerpts do not mention NSAIDs.
Taking Vascepa with medications like warfarin, aspirin, or ibuprofen can increase the risk of bleeding.
Label 5.3 supports increased bleeding with concomitant antithrombotic medications such as aspirin or warfarin, but the provided excerpts do not mention ibuprofen specifically.
There is no direct interaction between Vascepa and probiotics.
Provided Vascepa label excerpts contain no discussion of probiotics; therefore this statement is unsupported by the supplied labeling.
There is no conclusive evidence to suggest that Vascepa and probiotics cannot be taken together.
Provided label excerpts do not discuss probiotics; therefore this statement is unsupported.
There is no conclusive evidence to suggest that probiotics will reduce the effectiveness of Vascepa.
Provided label excerpts do not discuss probiotics or effects on Vascepa effectiveness; therefore unsupported.
Vascepa can interact with other medications, including antibiotics.
The provided label excerpt on drug interactions (7.1) discusses anticoagulants and antiplatelet agents; it does not mention antibiotics.
It is not recommended to take Vascepa and probiotics together if already taking blood thinners.
No probiotic-specific guidance is present in the provided label excerpts.
If taking Vascepa and probiotics together, bleeding risk and medication effectiveness should be monitored.
No probiotic-specific monitoring recommendations appear in the provided label excerpts.
Contradictions
Low
AI Statement
Vascepa reduces the risk of pancreatitis and other cardiovascular complications.
Label Reference
Label 1: “Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.”
Important Omissions
Indication includes adjunct to maximally tolerated statin therapy to reduce risk of specific cardiovascular events in adults with elevated TG and established CVD or diabetes plus additional risk factors.
Importance:
Moderate
No dosage details were provided (e.g., 4 g/day with specified capsule strengths and administration with food; swallow whole; do not break open/crush/dissolve/chew).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Contains several unsupported probiotic-related interaction recommendations and a pancreatitis-risk reduction claim that conflicts with the label limitation. Bleeding-risk statements for antithrombotics are partially aligned, but other interaction claims (NSAIDs/antibiotics) are not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Probiotic-related interaction claims and pancreatitis-risk reduction are not supported by the supplied Vascepa prescribing information (and pancreatitis claim contradicts the label limitation).
Suggested Improvement
Restrict Vascepa statements to the provided label excerpts: indications (including statin adjunct limitation details), documented bleeding risk and monitoring with anticoagulants/antiplatelet agents, and avoid probiotic interaction assertions unless the label contains relevant wording.